A Study of Stereotactic Radiosurgery (SRS) in People With Brain Cancer Having Tumor Resection Surgery
Key facts
- Who runs it
- Memorial Sloan Kettering Cancer Center
- Where
- Basking Ridge, Commack, Harrison, Middletown, Montvale, New York, and Rockville Centre, United StatesSee the 7 sites
- Trial code
- Status
- Recruiting
- People taking part
- 50 people, planned
- Started
- 28 Aug 2026
- Expected to end
- Aug 2028
- Type of study
- Interventional
- Treatments tested
- Stereotactic Radiosurgery
- Surgical Resection
- Record updated
- 9 September 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Histologically or cytologically confirmed breast cancer, non-small cell lung cancer, melanoma, or gastrointestinal cancer. In malignancies for which tissue confirmation is not standard diagnostic practice (for example, hepatocellular carcinoma diagnosed by characteristic imaging), radiographic diagnosis consistent with standard of care is acceptable. In all cases, the intracranial lesion planned for resection undergoes pathologic examination as part of protocol-directed surgery
- At least one intact brain metastasis is planned for surgical resection that has not previously received stereotactic radiosurgery or other focal radiotherapy, measuring 6 cm or less in diameter
- No evidence of leptomeningeal disease based on clinical symptoms, MRI imaging of the brain or spinal cord, and/or lumbar puncture cytologic analysis
- No prior SRS to the index BM planned for surgical resection. Prior SRS to non- index lesions is permitted, with approval from the principal investigator. The interval since prior cranial radiotherapy will be recorded. All clinically significant toxicities from prior radiotherapy must have resolved to grade 1 or lower (CTCAE); patients with unresolved symptomatic (grade 2 or higher) radiation necrosis, treatment-related enhancing treatment effect, or clinically significant cerebral edema attributable to prior cranial radiation are not eligible
- No prior therapeutic craniotomy or craniectomy with biopsy
- Age ≥ 18
- Karnofsky Performance Status (KPS) of ≥ 70 and anticipated survival of >1 year
- Ability to undergo contrast-enhanced MRI brain
Who cannot take part
- Prior whole brain radiotherapy
- Pregnant and/or breastfeeding
- Neurologic instability despite medical management, such that either the treating team or study investigators feel that urgent craniotomy without awaiting SRS is indicated
- Judgment by the principal investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements
Where in United States
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)Basking Ridge, United StatesContact: Luke Pike, MDTaking people
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)Commack, United StatesContact: Luke Pike, MDTaking people
- Memorial Sloan Kettering Westchester (Limited Protocol Activities)Harrison, United StatesContact: Luke Pike, MDTaking people
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities)Middletown, United StatesContact: Luke Pike, MDTaking people
- Memorial Sloan Kettering Bergen (Limited Protocol Activities)Montvale, United StatesContact: Luke Pike, MDTaking people
- Memorial Sloan Kettering Cancer Center (All Protocol Activities)New York, United StatesContact: Luke Pike, MDTaking people
- Memorial Sloan Kettering Nassau (Limited Protocol Activities)Rockville Centre, United StatesContact: Luke Pike, MDTaking people
About the trial
What the trial wants to find out
The researchers are doing this study to see if treating people's brain tumors with stereotactic radiosurgery (SRS) before tumor resection surgery will prevent cancer cells from spreading to other areas of the brain, including the fluid and lining around the brain, during surgery, and lead to better surgical outcomes and fewer complications after surgery (post-surgery complications). Only one brain tumor (the index tumor) will be treated with the study radiosurgery and then removed by surgery. If there are other brain tumors, they will not be removed by surgery in this study, although they may be treated separately with standard radiation if the doctor decides it is needed.
The group in the trial
- Stereotactic RadioSurgeryTreatment being tested
Patients will be seen by an attending radiation oncologist before receiving SRS. Standard of are history and physical will be obtained. An MRI brain with contrast will be performed within seven days of the CT simulation for SRS planning. Surgical resection of the index lesion is to be performed within 10 days of SRS, and no later than 21 days to accommodate operating room availability.
Treatment: Stereotactic Radiosurgery and Surgical Resection
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- PReoperative Dose Escalated Stereotactic radioSurgery for Resectable Brain Metastases (PRESS)
- Record updated
- 9 September 2026